H these angular methyl groups should prove to have useful pharmacological properties the task 0~< of the synthetic organic chemist would be so much simpler. The finding that 19-nortestosterone did resemble its natural analogue (III) in II~~its pharmacological properties (Dodds, Lawson 19-Norsteroid and Simpson, quoted by Birch, 1950b; Hershberger et al., 1953) led to a systematic study of and biological the 19-nor analogues of most of the steroid ost easily named hormones.
from their analogues in the "ordinary" steroid series with the prefix "19-nor-". Thus from testosterone (III) is derived 19-nortestosterone (IV). Systematic names may be based on "androstane" or "pregnane" (again with the prefix "19-nor") or on "oestrane" which is the hypothetical hydrocarbon V lacking a methyl group at C-10. Compounds studied.-A summary of the principal compounds of clinical interest is given in Tables I and II . They may be divided into two main groups, the 19-nor-ZLC3 ketones (Table I ) and the remainder (Table II) . TAaLz The compound which is of principal interest clinically as a protein-anabolic agent is 17aethyl-19-nortestosterone (XII, Nilevar) although other members of the same series have been found active in animal experiments (see, e.g., Saunders and Drill, 1956) . (Tullner and Hertz, 1953) and several members of the 17a-alkyl-19nortestosterone series have strong progestational activity (Saunders et al., 1957; Overbeek and Visser, 1956; Elton and Edgren, 1958) . Those which have found the widest clinical application are 17a-ethynyl-19-nortestosterone (XIII; norethisterone) and its 17ac-methyl anlogue (methylcestrenolone, MO; as XIII, but witb Me in place of C * CH).
19-Norprogesterone
Norethisterone and its A5(10)-isomer (XIV; norethynodrel) are powerful inhibitors of ovulation (Pincus, 1956; Pincus et al., 1956; Rock et al., 1957 Two miscellaneous activities of 19-nor steroids are as anti-aldosterone agents and as "lipidhifting" agents. The spirolactone (XV; SC81O9; Cella and Kagawa, 1957) has anti-aldosterone activity and causes sodium and water diuresis; the compound (XVI; SC6582; Cook et al., 1958) , which is the methyl analogue of norethynodrel, depresses the cholesterol-phospholipid ratio in cockerels. Colton et al. (1957) . Rapala and Farkas (1958a, b) ; Chen (1958 (1933) found that testicular extracts would increase kidney weight. Kochakian (1944) examined a large number of steroid substances for their relative effects on kidney and gonad weight and showed clearly that these effects did not vary in parallel.
Since then many workers have studied more specifically the effects of steroids on nitrogen retention and renal hypertrophy. It seemed at least possible that anabolic steroids might benefit patients with chronic renal disease not only by diminishing nitrogen turn-over, but by promoting regeneration of renal tissue. To this end, 19-nortestosterone phenylpropionate has been given to a small group of such patients. Selection of cases.-Patients were chosen who had sufficiently severe renal damage to cause considerable elevation of blood urea, and whose condition was approximately static. Several on whom study was commenced were discarded from the trial because dietary treatment alone brought the urea down to normal levels. Those eventually treated with steroid were two patients whose renal disease was attributable to ascending infections and two with polycystic kidneys.
Procedure.-Patients were given a diet of low protein content and calorie content estimated to be sufficient for their age, sex and activity. If, during the first few days, they found the diet excessive or insufficient, the calorie content was altered to try to match appetite and they were maintained at this level a few days more for stabilization before commencing balance study. Urine was collected in twenty-four-hour periods, measured and analysed for total nitrogen, urea, creatinine, potassium, sodium, phosphorus and calcium. Faces were not examined since, in the absence of bowel disturbance, fecal nitrogen is so much less than urinary nitrogen, is fairly constant in amount and has been shown by Kochakian (1950) in animals and by McSwiney and Prunty (1958) in man to be unaffected by anabolic steroids. Plasma or serum was analysed three times weekly for albumin, globulin, urea, K, Na, Cl, Ca, inorganic P and CO2 combining power. Body weight was measured under standard conditions of alimentation and excretion. Diet samples and unconsumed food and vomitus were analysed for N. In calculation of N "balance", the difference between actual N intake (food N minus N of unconsumed food+ vomit) and the N lost by the tissues has been Proceedings of the Roi used. The latter was calculated from total urine± the change in urea-N of the body fluids, the total body water being taken arbitrarily as 50 % of body weight.
19-nortestosterone phenylpropionate was given by intramuscular injection of 25 mg. in oil on alternate days. This dosage was much higher than that recommended by the manufacturers and was deliberately given to be sure of producing maximum N retention and to reveal any possible side effects. CASE REPORTS The findings on admission for study are given in Table I Fig. 1) . A nephrolithotomy had been performed in 1948. In 1953 there was generalized cedema and since 1955 recurrent episodes of vomiting. Her general condition was poor and she vomited on most days so that she was unable to take regularly the whole of the 30-gram protein diet supplied. On administering steroid there was definite reduction in amount of urea formed and of K excreted. N balance, from being markedly negative, came into approximate equilibrium. The failure to obtain more than a slight fall in blood urea despite the improvement in N balance was probably due to fall in urinary volume (there was no evidence in other patients that this steroid causes water retention). The severe acidosis and very low serum albumin remained unchanged. Case II.-M. G., female, aged 52 (Fig. 2 ). This patient had ascending pyelonephritis with a history of at least one year's duration. Although treated with antibiotics, the urine remained infected. She would accept only about 30 grams of the 40 grams protein she was given daily. Shortly after commencing steroid administration she developed pyrexia to which the initial rise in plasma urea and inorganic P is probably attributable since effective treatment with Terramycin was followed by marked progressive fall in both urea and P in plasma. At this stage it was possible to increase her diet to 50 grams protein daily without rise in plasma urea or P and only a slight rise in urine K; simultaneously N Figs. 1-4.-Metabolic data: Urine excretions are all daily outputs. In showing N "balance," actual N intake is measured downwards from the zero line and urea-N formed is measured upwards from the level of N intake as base. Account has not been taken of fxcal N. Case III.-A. W., male, aged 60 ( Fig. 3 ).
Symptoms first commenced at age 39 and the patient was subsequently in hospital repeatedly, the diagnosis being polycystic renal disease. On a diet of 40 grams protein and 2,750 calories he was approximately in N balance and his blood urea fell to 35 mg./100 ml. On commencing steroid treatment there was an immediate fall in urine N and K, in plasma urea and inorganic P and an increase in body weight; the N balance became strongly positive.
Case IV.-R. Y., male, aged 47 (Fig. 4 ).
This patient commenced to have hematuria three years previously. Examination revealed enormous polycystic kidneys. His general condition was good and he had been doing heavy manual work despite his severe renal damage. He was given 40 grams protein and 2,100 calories daily on which he was approximately in N balance. When steroid was given there was little apparent response except for a slight rise in body weight. After a week he began to find his diet insufficient-perhaps in itself an indication of improvement-and on increasing his diet to 50 grams protein and 2,300 calories, N balance became definitely positive and blood urea fell and there was a further rise in body weight. It seems possible that the initially poor response in this patient may have been due to deficient calorie intake.
Conclusions. -19-nortestosterone phenylpropionate causes N retention in patients with chronic renal disease and confirms the evidence of Gjorup and Thaysen (1958) and Szold et al. (1959) published while these studies were in progress. It diminishes K excretion in urine and appears to diminish N catabolism (as judged by the rate of urea formation). It does not appear to affect plasma albumin or globulin levels and in one case with severe acidosis there was no evidence of improvement. It has no effect on the urea clearance. In some patients it rapidly lowers elevated plasma inorganic P. There was no evidence of virilism or progestational activity, but the patients treated were all over 47 years.
It is a pleasure to record the liberality of When she was 13 her mother died and she was adopted by neighbours. These neighbours were subsequently divorced and she had then gone to live with her stepmother. In two years she had lost 2 st. in weight. Menstruation had become scanty and irregular. The clinical findings were consistent with anorexia nervosa. B.M.R.-35%. Suppliesofethylnortestosterone became available to us in 1956.' By this time she had lost a further 7 lb. in weight and amenorrhoea was persistent. Fig. 1 shows the effect of the steroid on nitrogen balance. There was a mean retention of about 3 grams per day, followed by a rebound on stopping the drug. She then received 25 mg. by intramuscular injection three times a week for ten weeks. During this time she ate heartily and gained about 1 lb. a week (Fig. 2) . After stopping the injections she lost 2-3 lb. (perhaps in part due to an attack of mumps) but later continued to gain weight. The total weight gain has been about 60 lb. No voice change or growth of hair was noted. Menstruation did not return spontaneously and she is now having cyclical aestrogen treatment. 
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;appetite. Her weight had fallen to 6 st. and she complained of loss of libido and amenorrhera. At 21 she had had a nervous breakdown when her engagement was broken off. She married at the age of 30 and was persuaded by her husband to take a full-time job instead of having children as she wished. She was a somewhat withdrawn, emaciated woman with excessive body hair. B.M.R. -30%; other findings consistent with anorexia nervosa. Ethyl-nortestosterone (Fig. 3) induced a nitrogen retention of about 4 grams daily. She then took 30 mg. daily by mouth for ten weeks (Fig. 4) . At the end of this period her weight had increased by 2 st. Libido had retumed but amenorrheea persisted. Her voice had become a little husky and more fine hair had appeared on the face, arms and legs. Bromsulphthalein excretion was normal. After a further three months menstruation was normal. Facial and body hair was removed and did not reappear. The voice did not become completely normal for twelve months. Eighteen months later, she remains well but her weight is now falling slowly and she has begun a further course of nortestosterone.
Dr. G. L. M. Swyer (London): Effects of Norsteroid Progestogens on the Endometrium It is generally agreed that cestrogen priming is necessary for progestational action on the endometrium. Without previous or concomitant cestrogenic stimulation, the endometrium may show little or no response even to large doses of progestogen. In what follows, therefore, it is to be understood that the effects refer to cestrogenprimed endometria.
A typical late secretory endometrium can be produced in oestrogen-primed castrate women, or women with secondary amenorrhoea, with several of the norsteroids, if given in sufficient dosage. For this purpose, 17a-methyl-19-nortestosterone (methylcestrenolone), 17a-ethynyl-19-nortestosterone (norethisterone, Primolut N) and norethisterone acetate are effective oral progestogens. This does not appear to be the case with norethynodrel,' which will be considered separately.
Estimates of the amount of norethisterone required to do this are from 75-200 mg. (total dose) given over ten days (Hertz et al., 1956; Ober, 1957; Kaiser, 1957; Pots, 1957; Swyer, 1959) ; of methylcestrenolone 150-250 mg. or more (Swyer, 1959) : and of norethisterone acetate, 20-80 mg. (Pots, 1958; Swyer, 1959) . Certain points must be emphasized. There is marked variation from one individual to another in sensitivity to these progestogens. Some patients with secondary amenorrhoea are markedly refractory but become more responsive with successive courses of treatment-a priming effect, in fact. Castrate women, adequately primed with cestrogen, are generally more 'The progestogen ingredient of Enavid, which contains 9-85 mg. together with 0-15 mg. of ethinylcestradiol-3-methyl ether. responsive than women with secondary amenorrhoea. In comparison with the amounts of norsteroids mentioned above, the comparable quantity of ethisterone is stated to be 2,500-4,000 mg. (Wied and Davis, 1958) . On this basis therefore, it may be said that methylaestrenolone is about 16 times as potent as ethisterone, norethisterone 23 times and norethisterone acetate 65 times as potent-these figures of course being only approximate. For progesterone by daily intramuscular injection, Wied and Davis (1958) state that a total dose of 280 mg. is required to produce a late secretory endometrium.
So far as qualitaztive effects are concerned, there is not much doubt that at the end of a ten-day course of methylcestrenolone, norethisterone or norethisterone acetate in appropriate dosage, the endometrium presents an appearance strictly comparable with that produced by stimulation with progesterone. This is certainly not so with Enavid, the effects of which are somewhat complicated, depending upon the class of patient, stage of the cycle when treatment is commenced, dosage, and duration of treatment.
When Enavid is given to normal women in a dose of 10 mg. daily from the fifth day of the cycle, rapid secretory transformation is obtained, subnuclear vacuolation being evident by the fourth to sixth day of treatment. By the eighth day of treatment there may be a mid-secretory appearance of the glands. Stromal activity and cedema also begin early. However, with continued treatment, late secretory appearances of the glands do not occur. Instead, the glands become less prominent, undergoing what has been termed exhaustion atrophy. Stromal growth, on the other hand, continues vigorously with considerable cedema, and large, pale-staining predecidual cells appear. If treatment is continued for thirty days or more, decidual transformation reaches a mid-pregnancy stage, with striking glandular atrophy. If the daily dose is 20 mg. more marked secretory activity may be seen after twenty days of treatment but otherwise the progression of changes is similar to that with the smaller dose.
When Enavid is given to normal women from the twelfth day of the cycle in a dose of 10 mg. daily, the glands, arrested at the late proliferative phase, become dilated and cystic, with flattened epithelium. In patients with anovular cycles or secondary amenorrhoea, 10 mg. of Enavid daily for twenty days produced irregular or tubular glands, with high or low columnar epithelium and a small amount of secretion; the stroma was cellular and moderately cedematous. With 20 mg. daily, rather more secretion and stromal cedema were produced (Roland, 1958 (Shah et al., 1958) of the effects of Enavid on patients with anovulatory cycles showed typical and atypical responses. In some cases, the localization of glycogen, alkaline phosphatase and lipids in the glandular and stromal cells was similar to that in normal women, but in others, deposition of glycogen and lipids was more prominent in the stromal and predecidual cells than in normal endometria. In a few instances, the distribution of alkaline phosphatase in the glands was characteristic of the proliferative and early secretory phases while that of the stromal glycogen and lipid was typical ofthe late secretory phase. There is little or no published information on the effects of long-continued treatment with other norsteroids.
When treatment with any of these progestogens is stopped, withdrawal bleeding usually occurs within a few days. It is moderate in amount, even if treatment has been prolonged so as to produce a well developed decidua, in which case an entire decidual cast may be passed.
Dr. Margaret C. N. Jackson (Crediton) mentioned some of the papers and discussions she had heard at the 6th International Conference on Planned Parenthood recently held in Delhi. Several of the scientists and clinicians concerned with the development of orally active progestational steroids were at the Conference and had made interesting contributions. The Proceedings of the Conference will be published elsewhere.
Mr. J. A. Chalmers (Worcester): The Clinical Uses of the 19-Norsteroids in Gynwcology
My contribution to this symposium is to describe the results which I have obtained in clinical practice with the use of two of the norsteroid preparations. The drug principally used has been Enavid, a preparation of norethynodrel plus 1-5y% of the 3-methyl ether of ethinyleestradiol. In addition, a small series of cases has been treated with methyl cestrenolone. On the whole, the results have been more satisfactory with Enavid, possibly due to the fact that the inherent cestrogenic potency of norethynodrel plus that of the added cestrogen, makes previous priming of the patient with oestrogen unnecessary. Enavid appears to be the most effective progestational agent which I have used, but I have no experience of other norsteroids which are also reported to be of value.
Dysfunctional bleeding.-The principal indication for the use of Enavid has been dysfunctional uterine bleeding and it has been found particularly useful in the metropathic type of lesion occurring in women in their 30's. In addition, we have treated adolescents and young adults and a number of older women; the majority of our cases, however, have been between the ages of 25 and 35 years. Dosage schedule.-In most instances, the dosage used has been 10 mg. daily for ten days from the fifteenth to the twenty-fourth days of the cycle. Where there has been break-through bleeding, the dosage has been raised in one or two instances to 20 mg. daily, and in one instance (Case 18) 20 mg. daily has been given from the fourth to the twenty-third day of the cycle with satisfactory results. In 3 cases the dosage has been reduced to 10 mg. on alternate days because of nausea.
The youngest group, comprising 8 patients, ranging in age from 12 to 24 years, complained of prolonged and often frequent cycles and, in one instance, of bleeding so heavy that blood transfusion was required on several occasions before she came under our care. This girl (Case 1) was admitted to hospital with severe bleeding but Enavid 10 mg. twice daily, together with bed-rest, led to very marked diminution within forty-eight hours and to cessation after a further forty-eight hours. Subsequent courses of 1Omg. daily from the fifteenth to the twenty-fourth day of six cycles led to a normal menstrual pattern of 6/28 and at this stage she became pregnant within a month ofher marriage. 6 further cases in this group were less severe but all showed a good response.
The only failure was in a 20-year-old girl (Case 8) who had continuous bleeding following her third, apparently normal, delivery. Curettage at six weeks and at five months produced only temporary relief and in each case yielded a scanty non-secretory endometrium. Enavid 10 mg. daily was given for two cycles from the fifteenth to the twenty-fourth day but as this failed to control her bleeding, the dosage was raised to 20 mg. daily. This produced temporary relief, but after a week's interval bleeding began again which was unmodified by two further courses of Enavid. There was no evidence of chorionepithelioma, but ten months after her confinement we were forced to undertake hysterectomy. The uterus was bulky and subinvoluted with a nonsecretory endometrium and cystic glandular hyperplasia. Her subsequent progress has been Section of Endocrinology perfectly satisfactory. In spite of her youth, she has a family of three children and normal marital relations continue as before.
14 patients in the age group 25 to 35 years complained of menorrhagia and a good response was obtained in all but one (Case 10) who was unable to tolerate the medication because of nausea.
Most of these cases complained of heavy and prolonged periods for up to a year, but one (Case 12), who had had excessive bleeding for five years, was restored to a normal cycle after only two courses of Enavid, and 2 more (Cases 16 and 17), with symptoms for two and five years respectively, after four courses. Case 15, with menorrhagia for two years, had six courses following which her cycle returned to 4/28 but she has now had amenorrhcea for six months, for which I can find no explanation.
In 5 out of 7 patients over the age of 35 years, a good response was obtained. A sixth (Case 28) responded well whilst on treatment but bleeding was so severe when this ceased that hysterectomy was undertaken. In the seventh (Case 29) vomiting was so severe that treatment had to be discontinued after the first cycle.
As in all series of patients suffering from dysfunctional bleeding, we have probably been dealing here with a variety of related conditions, but over the whole group we have succeeded in restoring a normal cycle in 24 cases out of 29 and in a large proportion of these treatment was required for only two or three cycles. It seems probabNe that relapse may occur in several cases tut it is hoped that occasional treatment from time to time will direct the endocrine control of menstruation into normal channels. This may enable us to reduce the need for surgical intervention toanextentwhichwe have not found possible with the endocrine agents hitherto available.
Dysmenorrhcea.-The treatment of primary dysmenorrheea with Enavid is, of course, based on the suppression of ovulation which is probably due to the inhibition of pituitary gonadotrophin Epstein et al., 1958) . This property has also been used to effect contraception Rice-Wray, 1957) . We have used 10 mg. daily from the fourth to the twenty-third day of the cycle in 7 cases and from the tenth to the thirtieth day in a patient with a 35-day cycle. Excellent results were obtained in 4 of these cases, aged from 18 to 36 years. In a fifth (Case 34) complete relief of pain was obtained but at the cost of severe nausea. It is hoped that continued administration will lead to improved tolerance, as has been found by and Rice-Wray (1957) and she is continuing medication on reduced dosage of 10 mg. on alternate days and an alkali. In the sixth (Case 35), a nullipara aged 25 years, no response was obtained either with cestriol, Enavid or dilatation and packing of the cervix. Pre-sacral neurectomy was carried out because of the severe incapacity which this girl was experiencing, with complete relief of symptoms. The seventh, a nullipara aged 35 years, obtained no relief when treated with Enavid for three cycles. As she is anxious for a child we believed that her waning fertility could best be maintained by an immediate surgical approach and a presacral neurectomy has been carried out here also with relief of symptoms. The eighth (Case 37) a nullipara aged 25 years, complained of gradually increasing dysmenorrhcea despite the fact that she had been married for two and a half years before she reported. Pain began seven to ten days before the onset of the period and was so severe that she had to remain in bed on the first day of the period and she also had frequent fainting and vomiting. The uterus was very small and congenitally retroflexed. Treatment with Enavid produced no improvement and so oestradiol monobenzoate 10 mg. was injected directly into the uterine muscle in an attempt to overcome this hypoplasia, as described by Field-Richards (1955) . This produced considerable improvement and during the past three months she has had no vomiting and has not been confined to bed.
Timing of menstruation.-In 2 cases, the duration of treatment with Enavid has been adjusted so as to induce withdrawal bleeding, in one case seven days after, and in the other case seven days before a period was due, to avoid bleecdng on a wedding day. Subsequent cycles were normal.
Side-eflects.-In 9 patients, a reaction to the drug has been noted. 2 of these complained of nausea alone, 3 of vomiting, 2 of nausea and vomiting and 1 of nausea and diarrhaea. The ninth complained of nausea and extreme lassitude. Pincus et al. (1958) suggest that these reactions are due in the main to the cestrogen component in the preparation and we have found that when a patient has persisted with medication, tolerance improves, usually by the second cycle. In 3 patients, the side-effects were of such severity that treatment was discontinued. In one girl with dysmenorrhcea (Case 34), as mentioned above, treatment was continued in spite of nausea because of the excellent effect on pain. It is interesting to note that Whitelaw (1958) observes that doses of more than 0-5 gram of progesterone may cause lassitude and it seems that the same effect has been observed in Case 20. Here also, a reduced dosage of 10 mg. on alternate days has enabled her to continue treatment for six cycles.
Intolerance of medication appears to be an insuperable difficulty in a small percentage of 23 517 518 Proceedings of the Royal Society of Medicine 24 cases but in the great majority, the drug is well tolerated.
Methylestrenolone.-Methyleestrenolone (17oxmethyl-l9-nortestosterone, Orgasterone), has been found to produce an intense progestational effect and to be of value in a variety of gyn=cological disorders (Andreoli, 1958) . Our experience here has been limited to 6 cases. In 2 of these, aged 37 and 32 respectively (Cases 38 and 17) menorrhagia occurred soon after the sixth full-term delivery. In both the cycle remained regular but the duration of the periods was increased and heavy loss continued in each for about ten days. Premenstrual curettage in Case 17 showed a non-secretory endometrium. Both were treated with methyleestrenolone 5 mg. daily from the fourteenth to the twenty-fourth day of three cycles. Neither showed any improvement. In Case 38 hysterectomy was carried out and the endometrium found to be in the normal secretory phase. Case 17 was treated with Enavid for six cycles and restored to a normal cycle 7/28 with normal loss. She continues on treatment for a further six months, after which it is hoped that spontaneous normal menstruation will be re-established.
A nullipara aged 37 years (Case 39) had an irregular menstrual cycle and bleeding lasted up to six weeks. Curettage showed a cystic glandular hyperplasia in a non-secretory endometrium and methylexstrenolone 5 mg. daily given from the fourteenth to the twenty-fourth day of two cycles restored a normal cycle of 4-5/28, which has been maintained spontaneously for nine months.
Case 40, also a nullipara aged 37 years, had a regular cycle with very heavy loss but the uterus contains a number of small fibroids. Two courses of methyloestrenolone produced no change in the amount of loss and it seems likely that surgical treatment will be required.
A very tall, eunuchoid child aged 15 years (Case 41) had never menstruated regularly, bleeding lasting from one to fourteen days with one to three weeks' interval. Methylcestrenolone 5 mg. daily for ten days produced a withdrawal bleeding. Subsequently a regular cycle was established and eight further courses of treatment given. While she was on treatment the cycle remained regular but once treatment was discontinued it reverted to 3/14. She remains on treatment with methylcestrenolone and we hope that soon her endogenous progesterone output will become adequate.
Case 22, a nullipara aged 24 years, complained of a brownish discharge for about seven days at mid-cycle and it was decided to try the effect of methyleestrenolone from the twelfth to the fifteenth day of the cycle in an attempt to prevent what is, in effect, a break-through bleeding. This proved ineffectual and indeed, her cycle was disturbed to about 3/14. Enavid 10 mg. daily was given from the fourteenth to the twenty-third day and the cycle restored to 5/2& with freedom from intermenstrual bleeding and discharge. After some months, following an emotional upset, she reverted to her former condition but with treatment with Enavid for two further cycles, a regular cycle was re-established which has been maintained spontaneously for several months.
We have found no side-effects attributable to the use of methyloestrenolone. It has been suggested that previous priming with cestrogen would have given us improved results (Tindall, 1958) in some of these cases; generally, however, our results with Enavid have been more satisfactory and we have concentrated on this preparation for the present in order to accumulate a worth-while experience with it.
Conclusion.-We are gradually extending the indications for which we are employing Enavid, which has become, during the past year, one of our principal endocrine therapeutic weapons. We have found it of value, particularly in menorrhagia due to dysfunctional bleeding; even when fibroids or other local lesions are present it has been helpful as an adjuvant to surgical treatment. In dysmenorrheea, our results so far encourage us to extend its use and there appears to be a big field for it in infertility and the treatment of threatened, recurrent and habitual abortion, in which conditions we are now studying its use. I am indebted to Messrs. G. D. Searle and Co. Ltd., of High Wycombe, and their Medical Director, Dr. G. R. Venning, and to Messrs. Organon Laboratories Ltd., of London and their Medical Director, Dr. W. J. Tindall, for supplies of the steroids which have been used in this investigation and for their guidance as to the relevant literature.
